Sign up to receive innovation news, event updates, and information from Mount Sinai Innovation Partners. #IndustryInsights #TechTrends #ExclusiveEvents #NetworkingOpportunities https://lnkd.in/dWtzPyb
Mount Sinai Innovation Partners
Hospitals and Health Care
New York, NY 5,633 followers
We're hiring! View our job openings: https://bit.ly/2kGuoUJ
About us
Mount Sinai Innovation Partners (MSIP), as part of the Icahn School of Medicine at Mount Sinai, facilitates the transfer of discovery from the laboratory to the marketplace, acting as the interface with commercial entities. MSIP is responsible for the full spectrum of commercialization activities required to bring the Icahn School of Medicine’s inventions to life. These activities include evaluating, patenting, marketing, and licensing new technologies, while also negotiating agreements for sponsored research, material transfer, and confidentiality. Blue Mountain Technologies is a MSIP program to enhance distribution of, and product development based on, Mount Sinai’s growing portfolio of novel reagents, diagnostics, and medical devices.
- Website
-
http://www.ip.mountsinai.org
External link for Mount Sinai Innovation Partners
- Industry
- Hospitals and Health Care
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Specialties
- technology transfer, startups, intellectual property management, licensing, healthcare, medical innovation, education, research innovation, technology development, and commercialization
Locations
-
Primary
Get directions
150 East 42nd St.
2nd Floor
New York, NY 10017, US
Employees at Mount Sinai Innovation Partners
Updates
-
David Reich, MD, the Horace W. Goldsmith Professor of Anesthesiology, Professor of Artificial Intelligence, and Professor of Pathology, at the Icahn School of Medicine at Mount Sinai, discusses his research regarding AI-powered alerts, showing promise in improving medical care. Learn more: https://lnkd.in/evpGeMg5
-
Mirna Chehade, MD, MPH, Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, discusses her research regarding the efficacy of Dupixent (dupilumab) treating children with eosinophilic esophagitis. Learn more from Drugs.com: https://lnkd.in/eCfc_Ndp
Dupilumab Ups Histologic Response for Pediatric Eosinophilic Esophagitis - Drugs.com MedNews
drugs.com
-
Christa McPhee, MD, at the Icahn School of Medicine at Mount Sinai, discusses her study regarding the association of type 2 inflammation and asthma with higher risk for coronary artery disease. Learn more: https://lnkd.in/eEiyGR4s
Asthma, type 2 inflammation associated with coronary artery disease
healio.com
-
Robert Rosenson, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai discusses his research regarding the use of the drug zodasiran (formerly ARO-ANG3), targeting triglycerides and other lipoprotein levels. Learn more: https://lnkd.in/eQmBVxGB
Gene Silencing Benefit of Zodasiran in Hyperlipidemia
medscape.com
-
Serdar Farhan, MD, Assistant Professor of Medicine and Cardiology at the Icahn School of Medicine at Mount Sinai, discusses his study that finds less invasive endovascular treatments work equally well in women as in men. Learn more: https://lnkd.in/ezfy9hTz
-
-
Eric Nestler, MD, PhD, the director of the Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai, discusses his research exploring how epigenetic changes in the brain affect drug-seeking behaviors. Learn more: https://lnkd.in/e4eErCCc
The proteins that drive drug addiction
chemistryworld.com
-
Did you know the Mount Sinai Ideas Network features the wide range of technologies in development currently helping patients? Check out the Ideas Network pipeline! https://lnkd.in/exA_zvAY
-
-
Sign up to receive innovation news, event updates, and information from Mount Sinai Innovation Partners. #IndustryInsights #TechTrends #ExclusiveEvents #NetworkingOpportunities https://lnkd.in/dWtzPyb
-
-
Mirna Chehade, MD, MPH, at the Icahn School of Medicine at Mount Sinai, discusses her research regarding the efficacy of Dupixent (dupilumab) treating children with eosinophilic esophagitis. Learn more from Drugs.com: https://lnkd.in/eCfc_Ndp
Dupilumab Ups Histologic Response for Pediatric Eosinophilic Esophagitis - Drugs.com MedNews
drugs.com